{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:22:00Z","timestamp":1791404520303,"version":"4.3.3"},"reference-count":127,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["5T32AG023481"],"award-info":[{"award-number":["5T32AG023481"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["5R01AG038791-09"],"award-info":[{"award-number":["5R01AG038791-09"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["1U19AG063911-01"],"award-info":[{"award-number":["1U19AG063911-01"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Tau Consortium"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuroscience Letters"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.neulet.2020.134919","type":"journal-article","created":{"date-parts":[[2020,5,4]],"date-time":"2020-05-04T16:12:59Z","timestamp":1588608779000},"page":"134919","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":92,"special_numbering":"C","title":["Targeting tau: Clinical trials and novel therapeutic approaches"],"prefix":"10.1016","volume":"731","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8304-6711","authenticated-orcid":false,"given":"Lawren","family":"VandeVrede","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam L.","family":"Boxer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9424-5986","authenticated-orcid":false,"given":"Manuela","family":"Polydoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.neulet.2020.134919_bib0005","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a033118","article-title":"Clinical neurology and epidemiology of the major neurodegenerative diseases","volume":"10","author":"Erkkinen","year":"2018","journal-title":"Cold Spring Harb. Perspect. Biol."},{"issue":"4","key":"10.1016\/j.neulet.2020.134919_bib0010","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1002\/ana.24897","article-title":"The burden of neurological disease in the United States: a summary report and call to action","volume":"81","author":"Gooch","year":"2017","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neulet.2020.134919_bib0015","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1146\/annurev.neuro.24.1.1121","article-title":"Neurodegenerative tauopathies","volume":"24","author":"Lee","year":"2001","journal-title":"Annu. Rev. Neurosci."},{"issue":"11","key":"10.1016\/j.neulet.2020.134919_bib0020","doi-asserted-by":"crossref","first-page":"4040","DOI":"10.1073\/pnas.83.11.4040","article-title":"Neurofibrillary tangles of Alzheimer disease share antigenic determinants with the axonal microtubule-associated protein tau (tau)","volume":"83","author":"Wood","year":"1986","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"4","key":"10.1016\/j.neulet.2020.134919_bib0025","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0197-4580(97)00056-0","article-title":"Frequency of stages of Alzheimer-related lesions in different age categories","volume":"18","author":"Braak","year":"1997","journal-title":"Neurobiol. Aging"},{"issue":"11","key":"10.1016\/j.neulet.2020.134919_bib0030","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1097\/NEN.0b013e318232a379","article-title":"Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years","volume":"70","author":"Braak","year":"2011","journal-title":"J. Neuropathol. Exp. Neurol."},{"issue":"4","key":"10.1016\/j.neulet.2020.134919_bib0035","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1111\/j.1365-2990.2008.00997.x","article-title":"The dorsal raphe nucleus shows phospho-tau neurofibrillary changes before the transentorhinal region in Alzheimer\u2019s disease. A precocious onset?","volume":"35","author":"Grinberg","year":"2009","journal-title":"Neuropathol. Appl. Neurobiol."},{"issue":"Pt 5","key":"10.1016\/j.neulet.2020.134919_bib0040","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1093\/brain\/aww027","article-title":"Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer\u2019s disease","volume":"139","author":"Ossenkoppele","year":"2016","journal-title":"Brain"},{"issue":"9","key":"10.1016\/j.neulet.2020.134919_bib0045","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1212\/01.WNL.0000063311.58879.01","article-title":"Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer\u2019s disease","volume":"60","author":"Giannakopoulos","year":"2003","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.neulet.2020.134919_bib0050","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1097\/NEN.0b013e31825018f7","article-title":"Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature","volume":"71","author":"Nelson","year":"2012","journal-title":"J. Neuropathol. Exp. Neurol."},{"issue":"4","key":"10.1016\/j.neulet.2020.134919_bib0055","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/0896-6273(89)90210-9","article-title":"Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer\u2019s disease","volume":"3","author":"Goedert","year":"1989","journal-title":"Neuron"},{"issue":"5825","key":"10.1016\/j.neulet.2020.134919_bib0060","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1126\/science.1141736","article-title":"Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer\u2019s disease mouse model","volume":"316","author":"Roberson","year":"2007","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.neulet.2020.134919_bib0065","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1002\/ana.24230","article-title":"Tau reduction prevents disease in a mouse model of Dravet syndrome","volume":"76","author":"Gheyara","year":"2014","journal-title":"Ann. Neurol."},{"issue":"13","key":"10.1016\/j.neulet.2020.134919_bib0070","doi-asserted-by":"crossref","first-page":"4225","DOI":"10.1002\/j.1460-2075.1990.tb07870.x","article-title":"Expression of separate isoforms of human tau protein: correlation with the tau pattern in brain and effects on tubulin polymerization","volume":"9","author":"Goedert","year":"1990","journal-title":"EMBO J."},{"issue":"6686","key":"10.1016\/j.neulet.2020.134919_bib0075","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1038\/31508","article-title":"Association of missense and 5\u2032-splice-site mutations in tau with the inherited dementia FTDP-17","volume":"393","author":"Hutton","year":"1998","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.neulet.2020.134919_bib0080","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1002\/ana.410430617","article-title":"Tau is a candidate gene for chromosome 17 frontotemporal dementia","volume":"43","author":"Poorkaj","year":"1998","journal-title":"Ann. Neurol."},{"issue":"2","key":"10.1016\/j.neulet.2020.134919_bib0085","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.1750-3639.1998.tb00162.x","article-title":"Frontotemporal dementia and Parkinsonism linked to chromosome 17: a new group of tauopathies","volume":"8","author":"Spillantini","year":"1998","journal-title":"Brain Pathol."},{"issue":"6","key":"10.1016\/j.neulet.2020.134919_bib0090","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/BF00296367","article-title":"Abnormal Tau proteins in progressive supranuclear palsy. Similarities and differences with the neurofibrillary degeneration of the Alzheimer type","volume":"81","author":"Flament","year":"1991","journal-title":"Acta Neuropathol."},{"issue":"6","key":"10.1016\/j.neulet.2020.134919_bib0095","first-page":"1496","article-title":"Ultrastructure and biochemical composition of paired helical filaments in corticobasal degeneration","volume":"145","author":"Ksiezak-Reding","year":"1994","journal-title":"Am. J. Pathol."},{"issue":"4","key":"10.1016\/j.neulet.2020.134919_bib0100","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s00401-002-0591-z","article-title":"Argyrophilic grain disease and Alzheimer\u2019s disease are distinguished by their different distribution of tau protein isoforms","volume":"104","author":"Tolnay","year":"2002","journal-title":"Acta Neuropathol."},{"issue":"2","key":"10.1016\/j.neulet.2020.134919_bib0105","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1097\/00005072-199602000-00004","article-title":"Specific pathological Tau protein variants characterize Pick\u2019s disease","volume":"55","author":"Delacourte","year":"1996","journal-title":"J. Neuropathol. Exp. Neurol."},{"issue":"Pt 3","key":"10.1016\/j.neulet.2020.134919_bib0110","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.brainresbull.2016.08.018","article-title":"Tau and tauopathies","volume":"126","author":"Arendt","year":"2016","journal-title":"Brain Res. Bull."},{"issue":"4","key":"10.1016\/j.neulet.2020.134919_bib0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.01.027","article-title":"Posttranslational modifications mediate the structural diversity of tauopathy strains","volume":"180","author":"Arakhamia","year":"2020","journal-title":"Cell"},{"issue":"7662","key":"10.1016\/j.neulet.2020.134919_bib0120","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/nature23002","article-title":"Cryo-EM structures of tau filaments from Alzheimer\u2019s disease","volume":"547","author":"Fitzpatrick","year":"2017","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.neulet.2020.134919_bib0125","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1007\/s00702-004-0221-0","article-title":"Post-translational modifications of tau protein in Alzheimer\u2019s disease","volume":"112","author":"Gong","year":"2005","journal-title":"J. Neural Transm. Vienna (Vienna)"},{"issue":"1","key":"10.1016\/j.neulet.2020.134919_bib0130","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/nrn.2015.1","article-title":"Tau in physiology and pathology","volume":"17","author":"Wang","year":"2016","journal-title":"Nat. Rev. Neurosci."},{"issue":"32","key":"10.1016\/j.neulet.2020.134919_bib0135","doi-asserted-by":"crossref","first-page":"24374","DOI":"10.1016\/S0021-9258(20)80536-5","article-title":"Microtubule-associated protein tau. Abnormal phosphorylation of a non-paired helical filament pool in Alzheimer disease","volume":"268","author":"Kopke","year":"1993","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.neulet.2020.134919_bib0140","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.neuron.2010.08.044","article-title":"Acetylation of tau inhibits its degradation and contributes to tauopathy","volume":"67","author":"Min","year":"2010","journal-title":"Neuron"},{"key":"10.1016\/j.neulet.2020.134919_bib0145","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/ncomms1255","article-title":"The acetylation of tau inhibits its function and promotes pathological tau aggregation","volume":"2","author":"Cohen","year":"2011","journal-title":"Nat. Commun."},{"issue":"10","key":"10.1016\/j.neulet.2020.134919_bib0150","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.jalz.2016.06.006","article-title":"Therapeutic strategies for the treatment of tauopathies: hopes and challenges","volume":"12","author":"Khanna","year":"2016","journal-title":"Alzheimers Dement."},{"issue":"18","key":"10.1016\/j.neulet.2020.134919_bib0155","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus sham control in infantile-onset spinal muscular atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.neulet.2020.134919_bib0160","series-title":"IONIS-HTT Rx (RG6042) Top-line Data Demonstrate Significant Reductions of Disease-Causing Mutant Huntingtin Protein in People With Huntington\u2019s Disease","author":"Ionis Pharmaceuticals","year":"2018"},{"issue":"2","key":"10.1016\/j.neulet.2020.134919_bib0165","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/nm.2613","article-title":"Tau deficiency induces parkinsonism with dementia by impairing APP-mediated iron export","volume":"18","author":"Lei","year":"2012","journal-title":"Nat. Med."},{"issue":"6","key":"10.1016\/j.neulet.2020.134919_bib0170","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1016\/j.neurobiolaging.2012.12.003","article-title":"Age-appropriate cognition and subtle dopamine-independent motor deficits in aged tau knockout mice","volume":"34","author":"Morris","year":"2013","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neulet.2020.134919_bib0175","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1750-1326-9-29","article-title":"Motor and cognitive deficits in aged tau knockout mice in two background strains","volume":"9","author":"Lei","year":"2014","journal-title":"Mol. Neurodegener."},{"issue":"31","key":"10.1016\/j.neulet.2020.134919_bib0180","doi-asserted-by":"crossref","first-page":"12887","DOI":"10.1523\/JNEUROSCI.2107-13.2013","article-title":"Antisense reduction of tau in adult mice protects against seizures","volume":"33","author":"DeVos","year":"2013","journal-title":"J. Neurosci."},{"issue":"374","key":"10.1016\/j.neulet.2020.134919_bib0185","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aag0481","article-title":"Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy","volume":"9","author":"DeVos","year":"2017","journal-title":"Sci. Transl. Med."},{"issue":"5","key":"10.1016\/j.neulet.2020.134919_bib0190","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.neuron.2016.04.042","article-title":"Increased 4R-Tau induces pathological changes in a human-tau mouse model","volume":"90","author":"Schoch","year":"2016","journal-title":"Neuron"},{"issue":"24","key":"10.1016\/j.neulet.2020.134919_bib0195","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1056\/NEJMe1904861","article-title":"Oligonucleotide treatment for huntington\u2019s disease","volume":"380","author":"Fischbeck","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.neulet.2020.134919_bib0200","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.molmed.2009.01.003","article-title":"Tau phosphorylation: the therapeutic challenge for neurodegenerative disease","volume":"15","author":"Hanger","year":"2009","journal-title":"Trends Mol. Med."},{"issue":"5","key":"10.1016\/j.neulet.2020.134919_bib0205","first-page":"595","article-title":"The role of tau kinases in Alzheimer\u2019s disease","volume":"13","author":"Dolan","year":"2010","journal-title":"Curr. Opin. Drug Discov. Devel."},{"issue":"29","key":"10.1016\/j.neulet.2020.134919_bib0210","doi-asserted-by":"crossref","first-page":"10804","DOI":"10.1073\/pnas.0400348101","article-title":"O-GlcNAcylation regulates phosphorylation of tau: a mechanism involved in Alzheimer\u2019s disease","volume":"101","author":"Liu","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"Pt 7","key":"10.1016\/j.neulet.2020.134919_bib0215","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1093\/brain\/awp099","article-title":"Reduced O-GlcNAcylation links lower brain glucose metabolism and tau pathology in Alzheimer\u2019s disease","volume":"132","author":"Liu","year":"2009","journal-title":"Brain"},{"issue":"15","key":"10.1016\/j.neulet.2020.134919_bib0220","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1007\/s00018-007-7045-7","article-title":"Glycogen synthase kinase 3: a key regulator of cellular fate","volume":"64","author":"Forde","year":"2007","journal-title":"Cell. Mol. Life Sci."},{"issue":"3","key":"10.1016\/j.neulet.2020.134919_bib0225","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1002\/1097-4547(20001101)62:3<463::AID-JNR16>3.0.CO;2-7","article-title":"Phosphorylation of human tau protein by microtubule-associated kinases: GSK3beta and cdk5 are key participants","volume":"62","author":"Flaherty","year":"2000","journal-title":"J. Neurosci. Res."},{"issue":"19","key":"10.1016\/j.neulet.2020.134919_bib0230","doi-asserted-by":"crossref","first-page":"6990","DOI":"10.1073\/pnas.0500466102","article-title":"Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo","volume":"102","author":"Noble","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"6","key":"10.1016\/j.neulet.2020.134919_bib0235","doi-asserted-by":"crossref","first-page":"922","DOI":"10.4088\/JCP.08m04606","article-title":"Lithium trial in Alzheimer\u2019s disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study","volume":"70","author":"Hampel","year":"2009","journal-title":"J. Clin. Psychiatry"},{"issue":"3","key":"10.1016\/j.neulet.2020.134919_bib0240","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1046\/j.1471-4159.2000.0721327.x","article-title":"The mood-stabilizing agent valproate inhibits the activity of glycogen synthase kinase-3","volume":"72","author":"Chen","year":"1999","journal-title":"J. Neurochem."},{"issue":"12","key":"10.1016\/j.neulet.2020.134919_bib0245","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1084\/jem.20081588","article-title":"Valproic acid inhibits Abeta production, neuritic plaque formation, and behavioral deficits in Alzheimer\u2019s disease mouse models","volume":"205","author":"Qing","year":"2008","journal-title":"J. Exp. Med."},{"issue":"13","key":"10.1016\/j.neulet.2020.134919_bib0250","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1212\/WNL.0b013e318230a16c","article-title":"Chronic divalproex sodium use and brain atrophy in Alzheimer disease","volume":"77","author":"Fleisher","year":"2011","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.neulet.2020.134919_bib0255","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1001\/archgenpsychiatry.2011.72","article-title":"Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease","volume":"68","author":"Tariot","year":"2011","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.neulet.2020.134919_bib0260","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.clineuro.2016.04.021","article-title":"Randomized placebo-controlled trial of sodium valproate in progressive supranuclear palsy","volume":"146","author":"Leclair-Visonneau","year":"2016","journal-title":"Clin. Neurol. Neurosurg."},{"issue":"6","key":"10.1016\/j.neulet.2020.134919_bib0265","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1021\/jm011020u","article-title":"First non-ATP competitive glycogen synthase kinase 3 beta (GSK-3beta) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer\u2019s disease","volume":"45","author":"Martinez","year":"2002","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.neulet.2020.134919_bib0270","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.nbd.2009.05.025","article-title":"A novel GSK-3beta inhibitor reduces Alzheimer\u2019s pathology and rescues neuronal loss in vivo","volume":"35","author":"Sereno","year":"2009","journal-title":"Neurobiol. Dis."},{"issue":"1","key":"10.1016\/j.neulet.2020.134919_bib0275","doi-asserted-by":"crossref","first-page":"205","DOI":"10.3233\/JAD-2012-120805","article-title":"Treatment of Alzheimer\u2019s disease with the GSK-3 inhibitor tideglusib: a pilot study","volume":"33","author":"del Ser","year":"2013","journal-title":"J. Alzheimers Dis."},{"issue":"1","key":"10.1016\/j.neulet.2020.134919_bib0280","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3233\/JAD-141959","article-title":"A phase II trial of tideglusib in Alzheimer\u2019s disease","volume":"45","author":"Lovestone","year":"2015","journal-title":"J. Alzheimers Dis."},{"issue":"4","key":"10.1016\/j.neulet.2020.134919_bib0285","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1002\/mds.25824","article-title":"A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy","volume":"29","author":"Tolosa","year":"2014","journal-title":"Mov. Disord."},{"issue":"4","key":"10.1016\/j.neulet.2020.134919_bib0290","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1002\/mds.25815","article-title":"Tideglusib reduces progression of brain atrophy in progressive supranuclear palsy in a randomized trial","volume":"29","author":"Hoglinger","year":"2014","journal-title":"Mov. Disord."},{"issue":"1","key":"10.1016\/j.neulet.2020.134919_bib0295","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/alzrt238","article-title":"Fyn kinase inhibition as a novel therapy for Alzheimer\u2019s disease","volume":"6","author":"Nygaard","year":"2014","journal-title":"Alzheimers Res. Ther."},{"issue":"22","key":"10.1016\/j.neulet.2020.134919_bib0300","doi-asserted-by":"crossref","first-page":"6465","DOI":"10.1021\/jm060434q","article-title":"N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5- (tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src\/Abl kinase inhibitor","volume":"49","author":"Hennequin","year":"2006","journal-title":"J. Med. Chem."},{"issue":"6","key":"10.1016\/j.neulet.2020.134919_bib0305","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1002\/ana.24394","article-title":"Fyn inhibition rescues established memory and synapse loss in Alzheimer mice","volume":"77","author":"Kaufman","year":"2015","journal-title":"Ann. Neurol."},{"issue":"1","key":"10.1016\/j.neulet.2020.134919_bib0310","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13195-015-0119-0","article-title":"A phase Ib multiple ascending dose study of the safety, tolerability, and central nervous system availability of AZD0530 (saracatinib) in Alzheimer\u2019s disease","volume":"7","author":"Nygaard","year":"2015","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.neulet.2020.134919_bib0315","doi-asserted-by":"crossref","DOI":"10.1001\/jamaneurol.2019.2050","article-title":"Effect of AZD0530 on cerebral metabolic decline in alzheimer disease: a randomized clinical trial","author":"van Dyck","year":"2019","journal-title":"JAMA Neurol."},{"issue":"28","key":"10.1016\/j.neulet.2020.134919_bib0320","doi-asserted-by":"crossref","first-page":"6584","DOI":"10.1523\/JNEUROSCI.1487-05.2005","article-title":"Tyrosine 394 is phosphorylated in Alzheimer\u2019s paired helical filament tau and in fetal tau with c-Abl as the candidate tyrosine kinase","volume":"25","author":"Derkinderen","year":"2005","journal-title":"J. Neurosci."},{"issue":"3","key":"10.1016\/j.neulet.2020.134919_bib0325","doi-asserted-by":"crossref","first-page":"503","DOI":"10.3233\/JPD-160867","article-title":"Nilotinib effects in parkinson\u2019s disease and dementia with Lewy bodies","volume":"6","author":"Pagan","year":"2016","journal-title":"J. Parkinsons Dis."},{"issue":"4","key":"10.1016\/j.neulet.2020.134919_bib0330","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/nchembio.797","article-title":"Increasing O-GlcNAc slows neurodegeneration and stabilizes tau against aggregation","volume":"8","author":"Yuzwa","year":"2012","journal-title":"Nat. Chem. Biol."},{"issue":"7","key":"10.1016\/j.neulet.2020.134919_bib0335","first-page":"P261","article-title":"Early clinical results and preclinical validation of the O-GlcNAcase (OGA) inhibitor MK-8719 as a novel therapeutic for the treatment of tauopathies","volume":"12","author":"Smith","year":"2016","journal-title":"Alzheimer's and Dementia"},{"key":"10.1016\/j.neulet.2020.134919_bib0340","series-title":"Alectos Therapeutics Announces FDA Orphan Drug Designation for MK-8719: An Investigational Small-molecule OGA Inhibitor for Treatment of Progressive Supranuclear Palsy","author":"Therapeutics","year":"2016"},{"issue":"7","key":"10.1016\/j.neulet.2020.134919_bib0345","first-page":"P227","article-title":"Pharmacological intervention with the novel o-glcnacase inhibitor ASN-561 reduces pathological tau in transgenic mice","volume":"11","author":"Permanne","year":"2015","journal-title":"Alzheimer's and Dementia"},{"issue":"7","key":"10.1016\/j.neulet.2020.134919_bib0350","first-page":"P251","article-title":"Phase 1 study in healthy volunteers of the O-glcnacase inhibitor ASN120290 as a novel therapy for progressive supranuclear palsy and related tauopathies","volume":"14","author":"Ryan","year":"2018","journal-title":"Alzheimer's and Dementia"},{"issue":"10","key":"10.1016\/j.neulet.2020.134919_bib0355","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1038\/nm.3951","article-title":"Critical role of acetylation in tau-mediated neurodegeneration and cognitive deficits","volume":"21","author":"Min","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.neulet.2020.134919_bib0360","doi-asserted-by":"crossref","DOI":"10.1002\/mdc3.12940","article-title":"Open-label phase 1 futility studies of salsalate and young plasma in progressive supranuclear palsy","author":"VandeVrede","year":"2020","journal-title":"Mov. Disord. Clin. Pract."},{"issue":"15","key":"10.1016\/j.neulet.2020.134919_bib0365","doi-asserted-by":"crossref","first-page":"9034","DOI":"10.1073\/pnas.1530287100","article-title":"Tau filaments from human brain and from in vitro assembly of recombinant protein show cross-beta structure","volume":"100","author":"Berriman","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"20","key":"10.1016\/j.neulet.2020.134919_bib0370","doi-asserted-by":"crossref","first-page":"11213","DOI":"10.1073\/pnas.93.20.11213","article-title":"Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines","volume":"93","author":"Wischik","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neulet.2020.134919_bib0375","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s40478-015-0204-4","article-title":"Preventive methylene blue treatment preserves cognition in mice expressing full-length pro-aggregant human Tau","volume":"3","author":"Hochgrafe","year":"2015","journal-title":"Acta Neuropathol. Commun."},{"issue":"14","key":"10.1016\/j.neulet.2020.134919_bib0380","doi-asserted-by":"crossref","first-page":"3716","DOI":"10.1093\/hmg\/ddu080","article-title":"Methylene blue upregulates Nrf2\/ARE genes and prevents tau-related neurotoxicity","volume":"23","author":"Stack","year":"2014","journal-title":"Hum. Mol. Genet."},{"issue":"4","key":"10.1016\/j.neulet.2020.134919_bib0385","doi-asserted-by":"crossref","first-page":"609","DOI":"10.4161\/auto.19048","article-title":"Methylthioninium chloride (methylene blue) induces autophagy and attenuates tauopathy in vitro and in vivo","volume":"8","author":"Congdon","year":"2012","journal-title":"Autophagy"},{"issue":"4","key":"10.1016\/j.neulet.2020.134919_bib0390","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.bcp.2013.12.008","article-title":"Tau-aggregation inhibitor therapy for Alzheimer\u2019s disease","volume":"88","author":"Wischik","year":"2014","journal-title":"Biochem. Pharmacol."},{"issue":"1","key":"10.1016\/j.neulet.2020.134919_bib0395","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1124\/jpet.114.219352","article-title":"Complex disposition of methylthioninium redox forms determines efficacy in tau aggregation inhibitor therapy for Alzheimer\u2019s disease","volume":"352","author":"Baddeley","year":"2015","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"10062","key":"10.1016\/j.neulet.2020.134919_bib0400","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1016\/S0140-6736(16)31275-2","article-title":"Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer\u2019s disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial","volume":"388","author":"Gauthier","year":"2016","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.neulet.2020.134919_bib0405","doi-asserted-by":"crossref","first-page":"435","DOI":"10.3233\/JAD-170560","article-title":"Potential of low dose leuco-methylthioninium bis(Hydromethanesulphonate) (LMTM) monotherapy for treatment of mild alzheimer\u2019s disease: cohort analysis as modified primary outcome in a phase III clinical trial","volume":"61","author":"Wilcock","year":"2018","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.neulet.2020.134919_bib0410","series-title":"TRX-237 Phase 3 Clinical Trial Update","author":"Pharmaceuticals","year":"2016"},{"issue":"4","key":"10.1016\/j.neulet.2020.134919_bib0415","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/embor.2013.15","article-title":"Physiological release of endogenous tau is stimulated by neuronal activity","volume":"14","author":"Pooler","year":"2013","journal-title":"EMBO Rep."},{"issue":"37","key":"10.1016\/j.neulet.2020.134919_bib0420","doi-asserted-by":"crossref","first-page":"13110","DOI":"10.1523\/JNEUROSCI.2569-11.2011","article-title":"In vivo microdialysis reveals age-dependent decrease of brain interstitial fluid tau levels in P301S human tau transgenic mice","volume":"31","author":"Yamada","year":"2011","journal-title":"J. Neurosci."},{"issue":"7","key":"10.1016\/j.neulet.2020.134919_bib0425","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/ncb1901","article-title":"Transmission and spreading of tauopathy in transgenic mouse brain","volume":"11","author":"Clavaguera","year":"2009","journal-title":"Nat. Cell Biol."},{"issue":"4","key":"10.1016\/j.neulet.2020.134919_bib0430","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.neuron.2011.11.033","article-title":"Propagation of tau pathology in a model of early Alzheimer\u2019s disease","volume":"73","author":"de Calignon","year":"2012","journal-title":"Neuron"},{"issue":"19","key":"10.1016\/j.neulet.2020.134919_bib0435","doi-asserted-by":"crossref","first-page":"12845","DOI":"10.1074\/jbc.M808759200","article-title":"Propagation of tau misfolding from the outside to the inside of a cell","volume":"284","author":"Frost","year":"2009","journal-title":"J. Biol. Chem."},{"issue":"10","key":"10.1016\/j.neulet.2020.134919_bib0440","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a024331","article-title":"Antibody therapeutics targeting abeta and tau","volume":"7","author":"Gallardo","year":"2017","journal-title":"Cold Spring Harb. Perspect. Med."},{"issue":"3","key":"10.1016\/j.neulet.2020.134919_bib0445","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s40259-016-0174-5","article-title":"Assessing the immunogenicity of biopharmaceuticals","volume":"30","author":"Pineda","year":"2016","journal-title":"BioDrugs"},{"issue":"9","key":"10.1016\/j.neulet.2020.134919_bib0450","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1212\/01.WNL.0000159740.16984.3C","article-title":"Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial","volume":"64","author":"Gilman","year":"2005","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.neulet.2020.134919_bib0455","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1001\/archneur.63.10.1459","article-title":"Tauopathy-like abnormalities and neurologic deficits in mice immunized with neuronal tau protein","volume":"63","author":"Rosenmann","year":"2006","journal-title":"Arch. Neurol."},{"issue":"3","key":"10.1016\/j.neulet.2020.134919_bib0460","doi-asserted-by":"crossref","first-page":"915","DOI":"10.3233\/JAD-140996","article-title":"N-terminal truncation of microtubule associated protein tau dysregulates its cellular localization","volume":"43","author":"Paholikova","year":"2015","journal-title":"J. Alzheimers Dis."},{"issue":"4","key":"10.1016\/j.neulet.2020.134919_bib0465","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/alzrt277","article-title":"Identification of structural determinants on tau protein essential for its pathological function: novel therapeutic target for tau immunotherapy in Alzheimer\u2019s disease","volume":"6","author":"Kontsekova","year":"2014","journal-title":"Alzheimers Res. Ther."},{"issue":"4","key":"10.1016\/j.neulet.2020.134919_bib0470","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/alzrt278","article-title":"First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer\u2019s disease model","volume":"6","author":"Kontsekova","year":"2014","journal-title":"Alzheimers Res. Ther."},{"issue":"2","key":"10.1016\/j.neulet.2020.134919_bib0475","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S1474-4422(16)30331-3","article-title":"Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer\u2019s disease: a randomised, double-blind, placebo-controlled, phase 1 trial","volume":"16","author":"Novak","year":"2017","journal-title":"Lancet Neurol."},{"issue":"1","key":"10.1016\/j.neulet.2020.134919_bib0480","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s13195-018-0436-1","article-title":"FUNDAMANT: an interventional 72-week phase 1 follow-up study of AADvac1, an active immunotherapy against tau protein pathology in Alzheimer\u2019s disease","volume":"10","author":"Novak","year":"2018","journal-title":"Alzheimers Res. Ther."},{"issue":"8","key":"10.1016\/j.neulet.2020.134919_bib0485","doi-asserted-by":"crossref","first-page":"e72301","DOI":"10.1371\/journal.pone.0072301","article-title":"Efficacy and safety of a liposome-based vaccine against protein Tau, assessed in tau.P301L mice that model tauopathy","volume":"8","author":"Theunis","year":"2013","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.neulet.2020.134919_bib0490","doi-asserted-by":"crossref","first-page":"e76523","DOI":"10.1371\/journal.pone.0076523","article-title":"Characterization of novel CSF Tau and ptau biomarkers for Alzheimer\u2019s disease","volume":"8","author":"Meredith","year":"2013","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.neulet.2020.134919_bib0495","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.neurobiolaging.2014.09.007","article-title":"Human secreted tau increases amyloid-beta production","volume":"36","author":"Bright","year":"2015","journal-title":"Neurobiol. Aging"},{"issue":"2","key":"10.1016\/j.neulet.2020.134919_bib0500","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/nrn3887","article-title":"Spreading of pathology in neurodegenerative diseases: a focus on human studies","volume":"16","author":"Brettschneider","year":"2015","journal-title":"Nat. Rev. Neurosci."},{"issue":"3","key":"10.1016\/j.neulet.2020.134919_bib0505","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s004010050978","article-title":"Phosphorylated serine422 on tau proteins is a pathological epitope found in several diseases with neurofibrillary degeneration","volume":"97","author":"Bussiere","year":"1999","journal-title":"Acta Neuropathol."},{"issue":"Pt 10","key":"10.1016\/j.neulet.2020.134919_bib0510","doi-asserted-by":"crossref","first-page":"2834","DOI":"10.1093\/brain\/awu213","article-title":"Neuronal uptake of tau\/pS422 antibody and reduced progression of tau pathology in a mouse model of Alzheimer\u2019s disease","volume":"137","author":"Collin","year":"2014","journal-title":"Brain"},{"key":"10.1016\/j.neulet.2020.134919_bib0515","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.trci.2018.10.007","article-title":"A randomized, single ascending dose study of intravenous BIIB092 in healthy participants","volume":"4","author":"Qureshi","year":"2018","journal-title":"Alzheimers Dement. N. Y. (N Y)"},{"issue":"6","key":"10.1016\/j.neulet.2020.134919_bib0520","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S1474-4422(19)30139-5","article-title":"Safety of the tau-directed monoclonal antibody BIIB092 in progressive supranuclear palsy: a randomised, placebo-controlled, multiple ascending dose phase 1b trial","volume":"18","author":"Boxer","year":"2019","journal-title":"Lancet Neurol."},{"issue":"3","key":"10.1016\/j.neulet.2020.134919_bib0525","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/acn3.176","article-title":"Anti-tau antibody reduces insoluble tau and decreases brain atrophy","volume":"2","author":"Yanamandra","year":"2015","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"2","key":"10.1016\/j.neulet.2020.134919_bib0530","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.neuron.2013.07.046","article-title":"Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo","volume":"80","author":"Yanamandra","year":"2013","journal-title":"Neuron"},{"issue":"386","key":"10.1016\/j.neulet.2020.134919_bib0535","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aal2029","article-title":"Anti-tau antibody administration increases plasma tau in transgenic mice and patients with tauopathy","volume":"9","author":"Yanamandra","year":"2017","journal-title":"Sci. Transl. Med."},{"issue":"4","key":"10.1016\/j.neulet.2020.134919_bib0540","first-page":"236","article-title":"Preclinical and clinical development of ABBV-8E12, a humanized anti-tau antibody, for treatment of alzheimer\u2019s disease and other tauopathies","volume":"4","author":"West","year":"2017","journal-title":"J. Prev. Alzheimers Dis."},{"issue":"6","key":"10.1016\/j.neulet.2020.134919_bib0545","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1016\/j.celrep.2016.06.099","article-title":"Antibody-mediated targeting of tau in vivo does not require effector function and microglial engagement","volume":"16","author":"Lee","year":"2016","journal-title":"Cell Rep."},{"issue":"7","key":"10.1016\/j.neulet.2020.134919_bib0550","first-page":"P592","article-title":"Preclinical characterization of an antibody [LY3303560] targeting aggregated tau","volume":"13","author":"Alam","year":"2017","journal-title":"Alzheimer's and Dementia"},{"issue":"7 Suppl","key":"10.1016\/j.neulet.2020.134919_bib0555","first-page":"P1271","article-title":"Pan-tau antibody Biib076 exhibits promising safety and biomarker profile in cynomolgus monkey toxicity study [abstract P4-039]","volume":"13","author":"Czerkowicz","year":"2018","journal-title":"Alzheimers Dement."},{"issue":"5","key":"10.1016\/j.neulet.2020.134919_bib0560","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s00401-018-1911-2","article-title":"Epitope determines efficacy of therapeutic anti-Tau antibodies in a functional assay with human Alzheimer Tau","volume":"136","author":"Courade","year":"2018","journal-title":"Acta Neuropathol."},{"issue":"6","key":"10.1016\/j.neulet.2020.134919_bib0565","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1093\/brain\/awz100","article-title":"Prevention of tau seeding and propagation by immunotherapy with a central tau epitope antibody","volume":"142","author":"Albert","year":"2019","journal-title":"Brain"},{"key":"10.1016\/j.neulet.2020.134919_bib0570","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1749-6632.1999.tb07884.x","article-title":"A novel signaling molecule for neuropeptide action: activity-dependent neuroprotective protein","volume":"897","author":"Gozes","year":"1999","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"1","key":"10.1016\/j.neulet.2020.134919_bib0575","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1124\/jpet.107.130526","article-title":"A neuronal microtubule-interacting agent, NAPVSIPQ, reduces tau pathology and enhances cognitive function in a mouse model of Alzheimer\u2019s disease","volume":"325","author":"Matsuoka","year":"2008","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"2","key":"10.1016\/j.neulet.2020.134919_bib0580","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.nbd.2009.02.011","article-title":"NAP protects memory, increases soluble tau and reduces tau hyperphosphorylation in a tauopathy model","volume":"34","author":"Shiryaev","year":"2009","journal-title":"Neurobiol. Dis."},{"issue":"5-6","key":"10.1016\/j.neulet.2020.134919_bib0585","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1159\/000348347","article-title":"A double-blind, placebo-controlled, ascending-dose, randomized study to evaluate the safety, tolerability and effects on cognition of AL-108 after 12 weeks of intranasal administration in subjects with mild cognitive impairment","volume":"35","author":"Morimoto","year":"2013","journal-title":"Dement. Geriatr. Cogn. Disord."},{"key":"10.1016\/j.neulet.2020.134919_bib0590","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/978-3-7091-6641-3_6","article-title":"Cognitive disturbances in progressive supranuclear palsy","volume":"42","author":"Litvan","year":"1994","journal-title":"J. Neural Transm. Suppl."},{"issue":"7","key":"10.1016\/j.neulet.2020.134919_bib0595","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/S1474-4422(14)70088-2","article-title":"Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2\/3 trial","volume":"13","author":"Boxer","year":"2014","journal-title":"Lancet Neurol."},{"issue":"41","key":"10.1016\/j.neulet.2020.134919_bib0600","doi-asserted-by":"crossref","first-page":"13861","DOI":"10.1523\/JNEUROSCI.3059-10.2010","article-title":"Epothilone D improves microtubule density, axonal integrity, and cognition in a transgenic mouse model of tauopathy","volume":"30","author":"Brunden","year":"2010","journal-title":"J. Neurosci."},{"issue":"4","key":"10.1016\/j.neulet.2020.134919_bib0605","first-page":"P668","article-title":"A randomized, double-blind, placebo-controlled, multiple ascending dose study to evaluate the safety, tolerability and pharmacokinetics of a microtubule stabilizer (BMS-241027) in healthy females","volume":"9","author":"Malamut","year":"2013","journal-title":"Alzheimer's and Dementia"},{"issue":"9","key":"10.1016\/j.neulet.2020.134919_bib0610","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1158\/1535-7163.MCT-12-0061","article-title":"TPI-287, a new taxane family member, reduces the brain metastatic colonization of breast cancer cells","volume":"11","author":"Fitzgerald","year":"2012","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.neulet.2020.134919_bib0615","article-title":"Reactions to multiple ascending doses of the microtubule stabilizer TPI-287 in patients with alzheimer disease, progressive supranuclear palsy, and corticobasal syndrome: a randomized clinical trial","author":"Tsai","year":"2019","journal-title":"JAMA Neurol."},{"issue":"5","key":"10.1016\/j.neulet.2020.134919_bib0620","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1021\/acsmedchemlett.9b00083","article-title":"Treatment of alzheimer\u2019s by PROTAC-Tau protein degradation","volume":"10","author":"Kargbo","year":"2019","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.neulet.2020.134919_bib0625","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.45457","article-title":"Targeted degradation of aberrant tau in frontotemporal dementia patient-derived neuronal cell models","volume":"8","author":"Silva","year":"2019","journal-title":"Elife"},{"issue":"41","key":"10.1016\/j.neulet.2020.134919_bib0630","doi-asserted-by":"crossref","first-page":"E4376","DOI":"10.1073\/pnas.1411649111","article-title":"Proteopathic tau seeding predicts tauopathy in vivo","volume":"111","author":"Holmes","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"7618","key":"10.1016\/j.neulet.2020.134919_bib0635","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nature19323","article-title":"The antibody aducanumab reduces Abeta plaques in Alzheimer\u2019s disease","volume":"537","author":"Sevigny","year":"2016","journal-title":"Nature"}],"container-title":["Neuroscience Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304394020301890?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304394020301890?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T20:33:15Z","timestamp":1759609995000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304394020301890"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":127,"alternative-id":["S0304394020301890"],"URL":"https:\/\/doi.org\/10.1016\/j.neulet.2020.134919","relation":{},"ISSN":["0304-3940"],"issn-type":[{"value":"0304-3940","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting tau: Clinical trials and novel therapeutic approaches","name":"articletitle","label":"Article Title"},{"value":"Neuroscience Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neulet.2020.134919","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"134919"}}